Advertisement
ADPT vs CDNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a StrongBuy and CDNA is a Hold.
Momentum Indicator for ADPT turns positive, indicating new upward trend
ADPT saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 75 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ADPT just turned positive on October 27, 2026. Looking at past instances where ADPT's MACD turned positive, the stock continued to rise in 45 of 54 cases over the following month. The odds of a continued upward trend are 83%.
ADPT moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ADPT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +12.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADPT advanced for three days, in 237 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ADPT broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ADPT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.246) is normal, around the industry mean (67.298). P/E Ratio (-69.950) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (13.966) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ADPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
CDNA in -13.72% downward trend, falling for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CDNA declined for three days, in 230 of 272 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for CDNA moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 25 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 54 cases where CDNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
CDNA broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CDNA as a result. In 79 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CDNA just turned positive on October 28, 2026. Looking at past instances where CDNA's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in 244 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 203 of 224 cases where CDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.549) is normal, around the industry mean (67.298). P/E Ratio (36.370) is within average values for comparable stocks, (4.239). CDNA's Projected Growth (PEG Ratio) (48.410) is very high in comparison to the industry average of (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.146) is also within normal values, averaging (9.775).
ADPT | CDNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 34 | 87 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 97 | 34 | |
PRICE GROWTH RATING 1..100 | 35 | 34 | |
P/E GROWTH RATING 1..100 | 79 | 4 | |
SEASONALITY SCORE 1..100 | 29 | 2 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADPT's Valuation (18) in the Hospital Or Nursing Management industry is significantly better than the same rating for CDNA (97) in the Medical Specialties industry. This means that ADPT’s stock grew significantly faster than CDNA’s over the last 12 months.
CDNA's Profit vs Risk Rating (87) in the Medical Specialties industry is in the same range as ADPT (100) in the Hospital Or Nursing Management industry. This means that CDNA’s stock grew similarly to ADPT’s over the last 12 months.
CDNA's SMR Rating (34) in the Medical Specialties industry is somewhat better than the same rating for ADPT (97) in the Hospital Or Nursing Management industry. This means that CDNA’s stock grew somewhat faster than ADPT’s over the last 12 months.
CDNA's Price Growth Rating (34) in the Medical Specialties industry is in the same range as ADPT (35) in the Hospital Or Nursing Management industry. This means that CDNA’s stock grew similarly to ADPT’s over the last 12 months.
CDNA's P/E Growth Rating (4) in the Medical Specialties industry is significantly better than the same rating for ADPT (79) in the Hospital Or Nursing Management industry. This means that CDNA’s stock grew significantly faster than ADPT’s over the last 12 months.
| ADPT | CDNA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| Advances ODDS (%) | 3 days ago 86% | 3 days ago 83% |
| Declines ODDS (%) | 10 days ago 85% | 7 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 1 FA rating(s) are green while CDNA’s FA Score has 1 green FA rating(s).
- ADPT’s FA Score: 1 green, 4 red.
- CDNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 5 TA indicator(s) are bullish while CDNA’s TA Score has 4 bullish TA indicator(s).
- ADPT’s TA Score: 5 bullish, 4 bearish.
- CDNA’s TA Score: 4 bullish, 4 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а +13.80% price change this week, while CDNA (@Medical Specialties) price change was -8.70% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.92%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +38.31%.
Reported Earning Dates
ADPT is expected to report earnings on Feb 16, 2027.
CDNA is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Medical Specialties (-4.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
ADPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ADPT has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADPT jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ADPT | 1D Price Change % | ||
|---|---|---|---|---|
| ADPT | 100% | -2.97% | ||
| AXON - ADPT | 56% Loosely correlated | -0.21% | ||
| PSNL - ADPT | 53% Loosely correlated | -0.44% | ||
| GH - ADPT | 51% Loosely correlated | -2.17% | ||
| NTRA - ADPT | 51% Loosely correlated | -2.62% | ||
| ARRY - ADPT | 50% Loosely correlated | -8.86% | ||
More | ||||
CDNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with ADPT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To CDNA | 1D Price Change % | ||
|---|---|---|---|---|
| CDNA | 100% | -4.32% | ||
| ADPT - CDNA | 38% Loosely correlated | -2.97% | ||
| ABT - CDNA | 37% Loosely correlated | -0.05% | ||
| TWST - CDNA | 34% Loosely correlated | -2.37% | ||
| PSNL - CDNA | 34% Loosely correlated | -0.44% | ||
| CSTL - CDNA | 33% Loosely correlated | +0.12% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ASTN | 37.70 | 5.67 | +17.70% |
| Defiance Daily Target 2X Short ASTS ETF (ASTN) | |||
| ACIO | 46.10 | -0.09 | -0.19% |
| Aptus Collared Investment Opportunity ETF (ACIO) | |||
| TEK | 32.96 | -0.22 | -0.66% |
| iShares Technology Opportunities Active ETF | |||
| BSCZ | 19.61 | -0.13 | -0.68% |
| Invesco BulletShares 2035 Corporate Bond ETF (BSCZ) | |||
| RVER | 32.33 | -0.83 | -2.51% |
| Trenchless Fund ETF (RVER) | |||